Enliven positive Phase 1 ELVN-001 data in CML, FDA alignment on 80 mg dose, Phase 3 design

 

Enliven Therapeutics reports positive Phase 1 ELVN-001 data in CML, gains FDA alignment on 80 mg dose and Phase 3 design

• Updated Phase 1 ELVN-001 data reported in previously treated chronic myeloid leukemia patients.
• FDA alignment supports 80 mg once-daily ELVN-001 dose and Phase 3 ENABLE-2 design, starting in second half 2026.

https://finviz.com/stock?t=ELVN&p=d